Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.

A chain transfer agent composition comprises at least one branched C.sub.10 mercaptan selected from 5-methyl-1-mercapto-nonane, 3-propyl-1-mercapto-heptane, 4-ethyl-1-mercapto-octane, 2-butyl-1-mercapto-hexane, 5-methyl-2-mercapto-nonane, 3-propyl-2-mercapto-heptane, 4-ethyl-2-mercapto-octane, 5-methyl-5-mercapto-nonane, or combinations thereof. The chain transfer agent composition can be a component of an emulsion polymerization mixture and can be used in a process for emulsion polymerization for the production of polymers, for example, via free-radical polymerization.

A chain transfer agent composition comprises at least one branched C.sub.10 mercaptan selected from 5-methyl-1-mercapto-nonane, 3-propyl-1-mercapto-heptane, 4-ethyl-1-mercapto-octane, 2-butyl-1-mercapto-hexane, 5-methyl-2-mercapto-nonane, 3-propyl-2-mercapto-heptane, 4-ethyl-2-mercapto-octane, 5-methyl-5-mercapto-nonane, or combinations thereof. The chain transfer agent composition can be a component of an emulsion polymerization mixture and can be used in a process for emulsion polymerization for the production of polymers, for example, via free-radical polymerization.

A solution-based system for printing a 3D structure is provided and includes a substrate; a first solution including an organic molecule including a functional group at each end for creation of self-assembled monolayers (SAMs) including a first self-assembled monolayer (SAM) as a building block for printing the 3D structure, wherein the first solution is applied to a surface of the substrate to form the first SAM including a first SAM surface as a basis for the 3D structure; a second solution including metal ions, wherein the substrate with the first SAM is immersed into the second solution, and wherein the first solution is applied to the substrate which is immersed in the second solution thereby obtaining molecular-metal SAMs to provide a multiple layered SAM material; and means for applying a force and forming the 3D structure from the multiple layered SAM material, wherein the 3D structure is provided on the substrate.

A solution-based system for printing a 3D structure is provided and includes a substrate; a first solution including an organic molecule including a functional group at each end for creation of self-assembled monolayers (SAMs) including a first self-assembled monolayer (SAM) as a building block for printing the 3D structure, wherein the first solution is applied to a surface of the substrate to form the first SAM including a first SAM surface as a basis for the 3D structure; a second solution including metal ions, wherein the substrate with the first SAM is immersed into the second solution, and wherein the first solution is applied to the substrate which is immersed in the second solution thereby obtaining molecular-metal SAMs to provide a multiple layered SAM material; and means for applying a force and forming the 3D structure from the multiple layered SAM material, wherein the 3D structure is provided on the substrate.

Disclosed are methods for preparing disulfide compounds through oxidative coupling of thiol compounds. Thiols are oxidized to the corresponding disulfide compound in high yield in presence of a base and a metal salt. The method uses low catalyst loadings and provides organic disulfide compounds with little to no byproducts.

Disclosed are methods for preparing disulfide compounds through oxidative coupling of thiol compounds. Thiols are oxidized to the corresponding disulfide compound in high yield in presence of a base and a metal salt. The method uses low catalyst loadings and provides organic disulfide compounds with little to no byproducts.

Compounds which directly inhibit IRE-1 activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

The compounds shown below are presented. The compounds have a bidentate binding group: thioctic acid (TA) with disulfide or its reduced form of dihydrolipoic acid (DHLA) with dithiol. In embodiments, the compounds form part of a dithiolate-based ligand-grafted gold nanoparticle (AuNP). A method includes: mixing a testing material with a dithiolate-based ligand-grafted AuNP probe in solution, thereby generating a test sample; chilling the test sample at a predetermined temperature for a period of time; subsequent to chilling the test sample, detecting a color of the test sample; and determining anti-icing effects of the testing material based on the color of the test sample.

##STR00001##

The compounds shown below are presented. The compounds have a bidentate binding group: thioctic acid (TA) with disulfide or its reduced form of dihydrolipoic acid (DHLA) with dithiol. In embodiments, the compounds form part of a dithiolate-based ligand-grafted gold nanoparticle (AuNP). A method includes: mixing a testing material with a dithiolate-based ligand-grafted AuNP probe in solution, thereby generating a test sample; chilling the test sample at a predetermined temperature for a period of time; subsequent to chilling the test sample, detecting a color of the test sample; and determining anti-icing effects of the testing material based on the color of the test sample.

##STR00001##